Disialoganglioside GD2 antigen (GD2)

Disialoganglioside GD2 antigen is a carbohydrate-containing sphingolipid (glycosphingolipid) present on the outer surface of many tumor cells, especially of neuroectodermal origin, including neuroblastoma, melanoma, and several other pediatric and adult solid tumors. Structurally, GD2 consists of a ceramide lipid tail and a branched carbohydrate (pentasaccharide) head group with two sialic acid residues, leading to its name. Its expression in normal tissues is primarily restricted to the central nervous system, skin melanocytes, and at lower levels in peripheral nerves, making it an attractive target for immunotherapy outside the CNS. GD2 plays a biological role in cell proliferation, invasion, and migration and can modulate the immune microenvironment to support tumor growth and immune evasion. Multiple anti-GD2 therapeutic approaches—including monoclonal antibodies, antibody-drug conjugates, CAR-T cells, and others—are in clinical use or investigation; however, significant toxicities such as neuropathic pain and peripheral neuropathy are associated with targeting GD2 due to some expression in normal tissues. GD2 surface expression is widely used as a diagnostic and disease-monitoring biomarker, particularly in neuroblastoma and other GD2-positive malignancies[1][2][3][4][5][6].

Other names

GD2 gangliosideDisialoganglioside GD2GD2 antigen

Antibody-dependent cell-mediated cytotoxicity (ADCC); Complement-dependent cytotoxicity (CDC); Direct apoptosis induction; CAR-T cell mediated lysis targeting GD2-expressing cells; Inhibition of cell adhesion and metastasis